Blockade of Adenosine A2A Receptor Enhances CD8 T Cells Response and Decreases Regulatory T Cells in Head and Neck Squamous Cell Carcinoma

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2017 Jun 9

PMID 28592285

Citations 96

Authors

Si-Rui Ma

Wei-Wei Deng

Jian-Feng Liu

Liang Mao

Guang-Tao Yu

Lin-Lin Bu

Ashok B Kulkarni

Wen-Feng Zhang

Zhi-Jun Sun

Affiliations

Soon will be listed here.

Abstract

Background: Cancer immunotherapy offers a promising approach in cancer treatment. The adenosine A2A receptor (A2AR) could protect cancerous tissues from immune clearance via inhibiting T cells response. To date, the role of A2AR in head and neck squamous cell carcinoma (HNSCC) has not been investigated. Here, we sought to explore the expression and immunotherapeutic value of A2AR blockade in HNSCC.

Methods: The expression of A2AR was evaluated by immunostaining in 43 normal mucosae, 48 dysplasia and 165 primary HNSCC tissues. The immunotherapeutic value of A2AR blockade was assessed in vivo in genetically defined immunocompetent HNSCC mouse model.

Results: Immunostaining of HNSCC tissue samples revealed that increased expression of A2AR on tumor infiltrating immune cells correlated with advanced pathological grade, larger tumor size and positive lymph node status. Elevated A2AR expression was also detected in recurrent HNSCC and HNSCC tissues with induction chemotherapy. The expression of A2AR was found to be significantly correlated with HIF-1α, CD73, CD8 and Foxp3. Furthermore, the increased population of CD4Foxp3 regulatory T cells (Tregs), which partially expressed A2AR, was observed in an immunocompetent mouse model that spontaneously develops HNSCC. Pharmacological blockade of A2AR by SCH58261 delayed the tumor growth in the HNSCC mouse model. Meanwhile, A2AR blockade significantly reduced the population of CD4 Foxp3 Tregs and enhanced the anti-tumor response of CD8 T cells.

Conclusions: These results offer a preclinical proof for the administration of A2AR inhibitor on prophylactic experimental therapy of HNSCC and suggest that A2AR blockade can be a potential novel strategy for HNSCC immunotherapy.

Citing Articles

Neoantigen mRNA vaccines and AA receptor antagonism: A strategy to enhance T cell immunity.

Imani S, Jabbarzadeh Kaboli P, Babaeizad A, Maghsoudloo M Hum Vaccin Immunother. 2025; 21(1):2458936.

PMID: 39882781 PMC: 11784654. DOI: 10.1080/21645515.2025.2458936.

The Neuroprotective Role of A2A Adenosine Purinoceptor Modulation as a Strategy Against Glioblastoma.

Simoes J, Braga G, Fontana M, Assmann C, Bagatini M Brain Sci. 2025; 14(12.

PMID: 39766485 PMC: 11674974. DOI: 10.3390/brainsci14121286.

Hypoxia-adenosinergic regulation of B cell responses.

Pruitt L, Abbott R Front Immunol. 2024; 15:1478506.

PMID: 39559353 PMC: 11570280. DOI: 10.3389/fimmu.2024.1478506.

GPCRs: emerging targets for novel T cell immune checkpoint therapy.

Dickinson K, Yee E, Vigil I, Schulick R, Zhu Y Cancer Immunol Immunother. 2024; 73(12):253.

PMID: 39358616 PMC: 11447192. DOI: 10.1007/s00262-024-03801-7.

Theoretical basis, state and challenges of living cell-based drug delivery systems.

Liu W, Cheng G, Cui H, Tian Z, Li B, Han Y Theranostics. 2024; 14(13):5152-5183.

PMID: 39267776 PMC: 11388066. DOI: 10.7150/thno.99257.

References

Estilo C, O-Charoenrat P, Talbot S, Socci N, Carlson D, Ghossein R . Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators by oligonucleotide microarray analysis. BMC Cancer. 2009; 9:11. PMC: 2649155. DOI: 10.1186/1471-2407-9-11. View

Ohta A, Gorelik E, Prasad S, Ronchese F, Lukashev D, Wong M . A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A. 2006; 103(35):13132-7. PMC: 1559765. DOI: 10.1073/pnas.0605251103. View

Hatfield S, Sitkovsky M . Oxygenation to improve cancer vaccines, adoptive cell transfer and blockade of immunological negative regulators. Oncoimmunology. 2015; 4(12):e1052934. PMC: 4635883. DOI: 10.1080/2162402X.2015.1052934. View

Quan J, Johnson N, Zhou G, Parsons P, Boyle G, Gao J . Potential molecular targets for inhibiting bone invasion by oral squamous cell carcinoma: a review of mechanisms. Cancer Metastasis Rev. 2011; 31(1-2):209-19. DOI: 10.1007/s10555-011-9335-7. View

Cekic C, Day Y, Sag D, Linden J . Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res. 2014; 74(24):7250-9. PMC: 4459782. DOI: 10.1158/0008-5472.CAN-13-3583. View

Whiteside T . The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008; 27(45):5904-12. PMC: 3689267. DOI: 10.1038/onc.2008.271. View

Sitkovsky M, Hatfield S, Abbott R, Belikoff B, Lukashev D, Ohta A . Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists. Cancer Immunol Res. 2014; 2(7):598-605. PMC: 4331061. DOI: 10.1158/2326-6066.CIR-14-0075. View

Takayama H, Trenn G, Sitkovsky M . Locus of inhibitory action of cAMP-dependent protein kinase in the antigen receptor-triggered cytotoxic T lymphocyte activation pathway. J Biol Chem. 1988; 263(5):2330-6. View

Bian Y, Terse A, Du J, Hall B, Molinolo A, Zhang P . Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway. Cancer Res. 2009; 69(14):5918-26. PMC: 2758611. DOI: 10.1158/0008-5472.CAN-08-4623. View

10.

Mittal D, Young A, Stannard K, Yong M, Teng M, Allard B . Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 2014; 74(14):3652-8. DOI: 10.1158/0008-5472.CAN-14-0957. View

11.

Yu G, Bu L, Zhao Y, Mao L, Deng W, Wu T . CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma. Oncoimmunology. 2016; 5(6):e1151594. PMC: 4938362. DOI: 10.1080/2162402X.2016.1151594. View

12.

Ohta A, Kini R, Ohta A, Subramanian M, Madasu M, Sitkovsky M . The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol. 2012; 3:190. PMC: 3389649. DOI: 10.3389/fimmu.2012.00190. View

13.

Sitkovsky M . T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol. 2009; 30(3):102-8. DOI: 10.1016/j.it.2008.12.002. View

14.

Curiel T, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P . Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10(9):942-9. DOI: 10.1038/nm1093. View

15.

Zhang B . CD73 promotes tumor growth and metastasis. Oncoimmunology. 2012; 1(1):67-70. PMC: 3376970. DOI: 10.4161/onci.1.1.18068. View

16.

Raskovalova T, Huang X, Sitkovsky M, Zacharia L, Jackson E, Gorelik E . Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J Immunol. 2005; 175(7):4383-91. DOI: 10.4049/jimmunol.175.7.4383. View

17.

Partlova S, Boucek J, Kloudova K, Lukesova E, Zabrodsky M, Grega M . Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma. Oncoimmunology. 2015; 4(1):e965570. PMC: 4368144. DOI: 10.4161/21624011.2014.965570. View

18.

Zarek P, Huang C, Lutz E, Kowalski J, Horton M, Linden J . A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood. 2007; 111(1):251-9. PMC: 2200810. DOI: 10.1182/blood-2007-03-081646. View

19.

Morote-Garcia J, Rosenberger P, Kuhlicke J, Eltzschig H . HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak. Blood. 2008; 111(12):5571-80. DOI: 10.1182/blood-2007-11-126763. View

20.

Allard B, Pommey S, Smyth M, Stagg J . Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res. 2013; 19(20):5626-35. DOI: 10.1158/1078-0432.CCR-13-0545. View